Jiangsu GDK Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 5.97%

Jiangsu GDK Biotechnology Co Ltd (688670) has an Asset Resilience Ratio of 5.97% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 688670 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥81.01 Million
≈ $11.85 Million USD Cash + Short-term Investments

Total Assets

CN¥1.36 Billion
≈ $198.42 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Jiangsu GDK Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Jiangsu GDK Biotechnology Co Ltd (688670) total assets.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu GDK Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688670 current and long-term liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥81.01 Million 5.97%
Total Liquid Assets CN¥81.01 Million 5.97%

Asset Resilience Insights

  • Limited Liquidity: Jiangsu GDK Biotechnology Co Ltd maintains only 5.97% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu GDK Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu GDK Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Abivax SA
PA:ABVX
Biotechnology 2.58%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%
Pulike Biological Engineering
SHG:603566
Biotechnology 17.82%
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 14.00%
NEWRON PHARMACEUT. EO-20
XETRA:NP5
Biotechnology 41.67%
Upstream Bio, Inc.
NASDAQ:UPB
Biotechnology 64.70%

Annual Asset Resilience Ratio for Jiangsu GDK Biotechnology Co Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Jiangsu GDK Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 7.69% CN¥109.05 Million
≈ $15.96 Million
CN¥1.42 Billion
≈ $207.59 Million
-5.06pp
2024-12-31 12.75% CN¥195.39 Million
≈ $28.59 Million
CN¥1.53 Billion
≈ $224.31 Million
+2.00pp
2023-12-31 10.75% CN¥175.42 Million
≈ $25.67 Million
CN¥1.63 Billion
≈ $238.75 Million
-10.63pp
2022-12-31 21.38% CN¥390.57 Million
≈ $57.15 Million
CN¥1.83 Billion
≈ $267.31 Million
-16.08pp
2021-12-31 37.46% CN¥657.31 Million
≈ $96.19 Million
CN¥1.75 Billion
≈ $256.74 Million
+32.32pp
2020-12-31 5.14% CN¥40.00 Million
≈ $5.85 Million
CN¥777.98 Million
≈ $113.84 Million
+2.84pp
2019-12-31 2.30% CN¥9.13 Million
≈ $1.34 Million
CN¥397.30 Million
≈ $58.14 Million
--
pp = percentage points

About Jiangsu GDK Biotechnology Co Ltd

SHG:688670 China Biotechnology
Market Cap
$342.53 Million
CN¥2.34 Billion CNY
Market Cap Rank
#14348 Global
#4316 in China
Share Price
CN¥19.00
Change (1 day)
+2.43%
52-Week Range
CN¥12.97 - CN¥30.90
All Time High
CN¥75.07
About

Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more